Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Daniel Lindner
Leronlimab Inhibits Colon Carcinoma Metastasis in a Humanized Mouse Xenograft Model
Submitted: 04 November 2025 You are already at the latest version Leronlimab, a humanized monoclonal antibody directed to the CCR5 receptor, demonstrated anti-tumor activity in humanized NSG mouse models of both heterotopic and orthotopic SW480 human colon carcinoma. The anti-tumor effect was lost in non-humanized mice, suggesting a critical role for engrafted human leukocytes. Development of xGVHD was delayed in both tumor-bearing and non-tumor-bearing mice that had been treated with leronlimab.
Invasive golden oyster mushrooms are disrupting native fungal communities as they spread throughout North America
Keywords invasive fungi impacts metabarcoding community composition fungal biodiversity mushroom cultivation Pleurotus citrinopileatus fungal ecology climate change Get full text access Log in, subscribe or purchase for full access. References 1. Pyšek, P. ∙ Hulme, P.E. ∙ Simberloff, D. ... Scientists’ warning on invasive alien species Biol. Rev. Camb. Philos. Soc. 2020; 95:1511-1534 2. Desprez-Loustau, M.L. ∙ Robin, C. ∙ Buée, M. ... The fungal dimension of biological invasions Trends Ecol. Evol.
Platinum Restoration Contrs., Inc. v. Salti, 2023 Ohio 4426 – CourtListener.com
[Cite as Platinum Restoration Contrs., Inc. v. Salti, 2023-Ohio-4426 .] COURT OF APPEALS OF OHIO EIGHTH APPELLATE DISTRICT COUNTY OF OHIO PLATINUM RESTORATION : CONTRACTORS, INC., : Plaintiff-Appellee, No. 112476 : v. FOWAZ SALTI, : Defendant-Appellant. : JOURNAL ENTRY AND OPINION JUDGMENT: REVERSED AND REMANDED RELEASED AND JOURNALIZED: December 7, 2023 Civil Appeal from the Cuyahoga County Court of Common Pleas Case No. CV-19-919506 Appearances: Davis & Young, Dennis R. Fogarty, and Ryan J.
CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma - Leukemia
Abstract T cell lymphomas (TCL) are heterogeneous, aggressive, and have few available targeted therapeutics. In this study, we determined that CD6, an established T cell marker, was expressed at high levels on almost all examined TCL patient specimens, suggesting that CD6 could be a new therapeutic target for this life-threatening blood cancer.
Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms - Leukemia
Abstract Myeloperoxidase (MPO) gene alterations with variable clinical penetrance have been found in hereditary MPO deficiency, but their leukemia association in patients and carriers has not been established. Germline MPO alterations were found to be significantly enriched in myeloid neoplasms: 28 pathogenic/likely pathogenic variants were identified in 100 patients. The most common alterations were c.2031-2 A > C, R569W, M519fs* and Y173C accounting for about half of the cases.
CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer
Abstract Small cell lung cancer (SCLC) is characterised by high relapse rates. Tumour-initiating cells (TICs) are responsible for drug resistance and recurrence of cancer.
Comment on the importance of using nitric oxide gas in the synthesis of nitrosylcobalamin and ICH-validated methods to assess purity and stability
This item requires a subscription to The Journal of Biological Chemistry.
The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells
AbstractTraditional treatments of small-cell lung cancer (SCLC) with cisplatin, a standard-of-care therapy, spare the tumor-initiating cells (TIC) that mediate drug resistance.
The FACT inhibitor CBL0137 synergizes with cisplatin in small cell lung cancer by increasing NOTCH1 expression and targeting tumor-initiating cells
AbstractTraditional treatments of small cell lung cancer (SCLC) with cisplatin, a standard of care therapy, spare the tumor-initiating cells (TIC) that mediate drug resistance. Here we report a novel therapeutic strategy that preferentially targets TIC in SCLC in which cisplatin is combined with CBL0137, an inhibitor of the histone chaperone facilitates chromatin transcription (FACT), which is highly expressed in TIC.
Diversity begets diversity in competition for space
Hutchinson, G. E. Homage to Santa Rosalia, or: Why are there so many kinds of animals? Am. Nat. 93, 145 (1959). Billick, I. & Case, T. J. Higher order interactions in ecological communities: what are they and how can they be detected? Ecology 75, 1529–1543 (1994). Baldrian, P. et al. Production of extracellular enzymes and degradation of biopolymers by saprotrophic microfungi from the upper layers of forest soil . Plant Soil 338, 111–125 (2010). Evans, J. A., Eyre, C. A., Rogers, H. J., Boddy, L. & Müller, C. T.
Emergence of a primary pathogen, the causative agent of bat white-nose syndrome: Chapter 28
Geomyces and Pseudogymnoascus (Fungi, Ascomycota, Leotiomycetes, aff. Thelebolales) are closely related groups of globally occurring soil-associated fungi. Recently, these genera of fungi have received attention because a newly identified species, Pseudogymnoascus (initially classified as Geomyces) destructans, was discovered in association with significant and unusual mortality of hibernating bats in North America (Blehert et al. 2009; Gargas et al. 2009; Minnis and Linder 2013).
First detection of bat white-nose syndrome in western North America
White-nose syndrome (WNS) is an emerging fungal disease of bats caused byPseudogymnoascus destructans. Since it was first detected near Albany, NY, in 2006, the fungus has spread across eastern North America, killing unprecedented numbers of hibernating bats. The devastating impacts of WNS on Nearctic bat species are attributed to the likely introduction ofP. destructans from Eurasia to naive host populations in eastern North America.
Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B cell lymphoma
Diffuse large B cell lymphoma (DLBCL) is a hematological cancer associated with an aggressive clinical course. The predominant subtypes of DLBCL display features of chronic or tonic B cell antigen receptor (BCR) signaling. However, it is not known if the spatial organization of the BCR contributes to regulation of pro-survival signaling pathways and cell growth.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Daniel
Contact Daniel, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack